Accelerating the development of therapeutic strategies for drug-resistant tuberculosis [PDF]
, 2018 Recent progress in the discovery, development and evaluation of new drugs and combination regimens for drug-resistant tuberculosis through greater collaboration between industry, donors and academia provides renewed hope for overcoming the challenges in ...
Tiberi, S, Vjecha, MJ, Zumla, A
core +1 more source
Infection and Drug Resistance, 2023 Tianhui Gao,1,* Cong Yao,1,* Yuanyuan Shang,1 Renchun Su,1 Xuxia Zhang,1 Weicong Ren,1 Shanshan Li,1 Wei Shu,2 Yu Pang,1 Qi Li2 1Department of Bacteriology and Immunology, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Gao T +9 more
doaj
Optimising linezolid use for drug-resistant tuberculosis: pharmacokinetics, toxicity, and resistance [PDF]
, 2022 Background: Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. There is a need for more effective, safe, and well-tolerated drugs. Linezolid is
Wasserman, Sean Adam
core +1 more source
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies [PDF]
, 2018 Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant
du Plessis, N +13 more
core +1 more source
REVISÃO SISTEMÁTICA SOBRE INVESTIGAÇÕES IN VITRO VOLTADAS PARA O TRATAMENTO DA TUBERCULOSE RESISTENTE E MULTIDROGA-RESISTENTE [PDF]
, 2021 Introduction: Tuberculosis is caused by variants of the Mycobacterium tuberculosis species, mainly affecting immunocompromised individuals. In this sense, the tuberculosis bacillus in its multi-resistant (MDR) and extremely resistant (XDR) forms has ...
Rocha Pinheiro Machado, Rachel +2 more
core +2 more sources
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children [PDF]
, 2023 Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and millions of deaths each year. Around 10% of these cases are in children, but only a fraction receive proper diagnosis and treatment. The spread of drug-resistant (DR)
Hanzhao Zhu +9 more
core +1 more source
Treatment optimisation of multidrug-resistant tuberculosis [PDF]
, 2023 A successful treatment outcome is seen in only 60% of persons treated for multidrugresistant tuberculosis (MDR-TB) worldwide, defined as resistance to both rifampicin and isoniazid.
Kuhlin, Johanna
core +1 more source
Candidate anti-tuberculosis medicines and regimens under clinical evaluation [PDF]
Background: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030.
Barros-Aguirre, David +7 more
core +1 more source
Targeting the serine pathway:a promising approach against tuberculosis? [PDF]
, 2019 Tuberculosis is still the leading cause of death by a single infectious agent. Effective chemotherapy has been used and improved since the 1950s, but strains resistant to this therapy and most antibacterial drugs on the market are emerging.
Haufroid, Marie, Wouters, Johan
core +1 more source
Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study. [PDF]
Infect Drug ResistGuanglu Jiang,1,* Rongmei Liu,2,* Yi Xue,1 Qiping Ge,2 Lihui Nie,2 Zizheng Lv,2 Zhongshun Kong,2 Jin Shi,2 Hongmei Chen,2 Hua Li,2 Xiaoguang Wu,2 Li Xie,2 Yanhua Song,2 Hairong Huang,1 Mengqiu Gao2 1National Clinical Laboratory on Tuberculosis ...
Jiang G +14 more
europepmc +3 more sources